2022-12-29 · Strategic equity investment · EUR 15 million ↗
The announcement concerns a signed definitive investment agreement. A USD 26.3 million Series B was also disclosed on 2022-02-01. Latest closing status and subsequent financing were not verified.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Uses mRNA technology to develop respiratory treatments; official disclosures report 2022 financing and a strategic investment from Cipla.
Program / service
Target / indication
Representative stage
Evidence & scope
RNA / delivery technology platform
Project-dependent / not verified · Project-dependent / not verified
Not verified
This record does not establish human validation of the entire platform
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.
Ethris signed a €30 million financing agreement with the European Investment Bank under HERA Invest to support respiratory mRNA medicines. Its development platform pairs stabilized mRNA with lipid nanoparticles designed for local respiratory delivery, with programs spanning respiratory disease and mucosal vaccines. The announcement describes bank financing, not an equity round or an unconditional grant, and does not establish clinical success.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Moderna announced Canadian authorization of mFLUSIVA, its mRNA influenza vaccine, and mCOFLU, its combined influenza and COVID-19 vaccine, for adults 50 and older. The November 5 announcement cites Phase 3 efficacy evidence for mFLUSIVA and immunogenicity comparisons for mCOFLU. The company said it would engage Canadian authorities and immunization partners on future availability.
